Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.
Epitomee Medical Ltd (EPIT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.416x
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has a cash flow conversion efficiency ratio of -0.416x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-12.78 Million) by net assets (ILA30.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Epitomee Medical Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Epitomee Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Epitomee Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epitomee Medical Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Starhedge SA
WAR:SHG
|
-0.004x |
|
Cheops Technology France SA
PA:MLCHE
|
N/A |
|
Venus Concept Inc
NASDAQ:VERO
|
-1.560x |
|
Tarku Resources Ltd
OTCQB:TRKUF
|
0.001x |
|
HAYNES INTL
BE:HYVN
|
0.050x |
|
CardioComm Solutions Inc
PINK:EKGGF
|
0.154x |
|
M.O.B.A. Network AB (publ)
PINK:MOBNF
|
0.005x |
|
Sydinvest Fjernøsten Akkumulerende KL
CO:SYIFJERADKKA
|
N/A |
Annual Cash Flow Conversion Efficiency for Epitomee Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Epitomee Medical Ltd from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA33.95 Million | ILA-8.29 Million | -0.244x | -7.30% |
| 2023-12-31 | ILA34.80 Million | ILA-7.92 Million | -0.228x | +4.69% |
| 2022-12-31 | ILA39.45 Million | ILA-9.42 Million | -0.239x | -121.08% |
| 2021-12-31 | ILA53.30 Million | ILA-5.76 Million | -0.108x | -106.37% |
| 2020-12-31 | ILA3.98 Million | ILA6.75 Million | 1.697x | +519.62% |
| 2019-12-31 | ILA6.89 Million | ILA-2.79 Million | -0.404x | -- |